CHEMOIMMUNOTHERAPY OF ADULT ACUTE LEUKÆMIA PROLONGATION OF REMISSION IN MYELOBLASTIC LEUKÆMIA WITH B.C.G.

J. U. Gutterman, V. Rodriguez, G. Mavligit, M. A. Burgess, E. Gehan, Evan M Hersh, K. B. Mccredie, R. Reed, T. Smith, G. P. Bodey, E. J. Freireich

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

The benefit of B.C.G. in prolonging chemotherapy-maintained complete remissions in adult acute leukæmia was studied. Twenty consecutive patients received intermittent chemoimmunotherapy with cytarabine, vincristine, prednisone (O.A.P.), and liquid Pasteur B.C.G. administered by scarification. The durations of remission were compared with those of a similar group of thirty-three consecutive patients maintained on O.A.P. chemotherapy alone. Eleven of the twenty (55%) O.A.P.+ B.C.G. treated patients remain in remission with an estimated median duration of 91 weeks. Only 14 of 33 patients (42%) maintained on O.A.P. remain in remission with a median duration of 50 weeks (P= 0·03). Immunotherapy was significant only for patients with acute myeloblastic leukæmia (A.M.L.) and not for lymphoblastic or undifferentiated leukæmia. Thus, ten of fourteen A.M.L. patients maintained on O.A.P.+B.C.G. are in remission (median duration 72 + weeks) compared with nine of twenty-one O.A.P.-maintained patients (median duration 60 weeks) (P=0·04). General immunocompetence was augmented by B.C.G. The best prognostic immunological test was the patients' in-vitro lymphocyte blastogenic reactivity to autologous remission bone-marrow cells: all five patients who reacted vigorously have relapsed compared with none of the six who failed to react or reacted weakly.

Original languageEnglish (US)
Pages (from-to)1405-1409
Number of pages5
JournalThe Lancet
Volume304
Issue number7894
DOIs
StatePublished - Dec 14 1974
Externally publishedYes

Fingerprint

Mycobacterium bovis
Immunocompetence
Drug Therapy
Immunologic Tests
Cytarabine
Vincristine
Prednisone
Bone Marrow Cells
Immunotherapy
Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gutterman, J. U., Rodriguez, V., Mavligit, G., Burgess, M. A., Gehan, E., Hersh, E. M., ... Freireich, E. J. (1974). CHEMOIMMUNOTHERAPY OF ADULT ACUTE LEUKÆMIA PROLONGATION OF REMISSION IN MYELOBLASTIC LEUKÆMIA WITH B.C.G. The Lancet, 304(7894), 1405-1409. https://doi.org/10.1016/S0140-6736(74)90070-1

CHEMOIMMUNOTHERAPY OF ADULT ACUTE LEUKÆMIA PROLONGATION OF REMISSION IN MYELOBLASTIC LEUKÆMIA WITH B.C.G. / Gutterman, J. U.; Rodriguez, V.; Mavligit, G.; Burgess, M. A.; Gehan, E.; Hersh, Evan M; Mccredie, K. B.; Reed, R.; Smith, T.; Bodey, G. P.; Freireich, E. J.

In: The Lancet, Vol. 304, No. 7894, 14.12.1974, p. 1405-1409.

Research output: Contribution to journalArticle

Gutterman, JU, Rodriguez, V, Mavligit, G, Burgess, MA, Gehan, E, Hersh, EM, Mccredie, KB, Reed, R, Smith, T, Bodey, GP & Freireich, EJ 1974, 'CHEMOIMMUNOTHERAPY OF ADULT ACUTE LEUKÆMIA PROLONGATION OF REMISSION IN MYELOBLASTIC LEUKÆMIA WITH B.C.G.', The Lancet, vol. 304, no. 7894, pp. 1405-1409. https://doi.org/10.1016/S0140-6736(74)90070-1
Gutterman, J. U. ; Rodriguez, V. ; Mavligit, G. ; Burgess, M. A. ; Gehan, E. ; Hersh, Evan M ; Mccredie, K. B. ; Reed, R. ; Smith, T. ; Bodey, G. P. ; Freireich, E. J. / CHEMOIMMUNOTHERAPY OF ADULT ACUTE LEUKÆMIA PROLONGATION OF REMISSION IN MYELOBLASTIC LEUKÆMIA WITH B.C.G. In: The Lancet. 1974 ; Vol. 304, No. 7894. pp. 1405-1409.
@article{2f4d117aa3e947a3953b5eb208a35d01,
title = "CHEMOIMMUNOTHERAPY OF ADULT ACUTE LEUK{\AE}MIA PROLONGATION OF REMISSION IN MYELOBLASTIC LEUK{\AE}MIA WITH B.C.G.",
abstract = "The benefit of B.C.G. in prolonging chemotherapy-maintained complete remissions in adult acute leuk{\ae}mia was studied. Twenty consecutive patients received intermittent chemoimmunotherapy with cytarabine, vincristine, prednisone (O.A.P.), and liquid Pasteur B.C.G. administered by scarification. The durations of remission were compared with those of a similar group of thirty-three consecutive patients maintained on O.A.P. chemotherapy alone. Eleven of the twenty (55{\%}) O.A.P.+ B.C.G. treated patients remain in remission with an estimated median duration of 91 weeks. Only 14 of 33 patients (42{\%}) maintained on O.A.P. remain in remission with a median duration of 50 weeks (P= 0·03). Immunotherapy was significant only for patients with acute myeloblastic leuk{\ae}mia (A.M.L.) and not for lymphoblastic or undifferentiated leuk{\ae}mia. Thus, ten of fourteen A.M.L. patients maintained on O.A.P.+B.C.G. are in remission (median duration 72 + weeks) compared with nine of twenty-one O.A.P.-maintained patients (median duration 60 weeks) (P=0·04). General immunocompetence was augmented by B.C.G. The best prognostic immunological test was the patients' in-vitro lymphocyte blastogenic reactivity to autologous remission bone-marrow cells: all five patients who reacted vigorously have relapsed compared with none of the six who failed to react or reacted weakly.",
author = "Gutterman, {J. U.} and V. Rodriguez and G. Mavligit and Burgess, {M. A.} and E. Gehan and Hersh, {Evan M} and Mccredie, {K. B.} and R. Reed and T. Smith and Bodey, {G. P.} and Freireich, {E. J.}",
year = "1974",
month = "12",
day = "14",
doi = "10.1016/S0140-6736(74)90070-1",
language = "English (US)",
volume = "304",
pages = "1405--1409",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "7894",

}

TY - JOUR

T1 - CHEMOIMMUNOTHERAPY OF ADULT ACUTE LEUKÆMIA PROLONGATION OF REMISSION IN MYELOBLASTIC LEUKÆMIA WITH B.C.G.

AU - Gutterman, J. U.

AU - Rodriguez, V.

AU - Mavligit, G.

AU - Burgess, M. A.

AU - Gehan, E.

AU - Hersh, Evan M

AU - Mccredie, K. B.

AU - Reed, R.

AU - Smith, T.

AU - Bodey, G. P.

AU - Freireich, E. J.

PY - 1974/12/14

Y1 - 1974/12/14

N2 - The benefit of B.C.G. in prolonging chemotherapy-maintained complete remissions in adult acute leukæmia was studied. Twenty consecutive patients received intermittent chemoimmunotherapy with cytarabine, vincristine, prednisone (O.A.P.), and liquid Pasteur B.C.G. administered by scarification. The durations of remission were compared with those of a similar group of thirty-three consecutive patients maintained on O.A.P. chemotherapy alone. Eleven of the twenty (55%) O.A.P.+ B.C.G. treated patients remain in remission with an estimated median duration of 91 weeks. Only 14 of 33 patients (42%) maintained on O.A.P. remain in remission with a median duration of 50 weeks (P= 0·03). Immunotherapy was significant only for patients with acute myeloblastic leukæmia (A.M.L.) and not for lymphoblastic or undifferentiated leukæmia. Thus, ten of fourteen A.M.L. patients maintained on O.A.P.+B.C.G. are in remission (median duration 72 + weeks) compared with nine of twenty-one O.A.P.-maintained patients (median duration 60 weeks) (P=0·04). General immunocompetence was augmented by B.C.G. The best prognostic immunological test was the patients' in-vitro lymphocyte blastogenic reactivity to autologous remission bone-marrow cells: all five patients who reacted vigorously have relapsed compared with none of the six who failed to react or reacted weakly.

AB - The benefit of B.C.G. in prolonging chemotherapy-maintained complete remissions in adult acute leukæmia was studied. Twenty consecutive patients received intermittent chemoimmunotherapy with cytarabine, vincristine, prednisone (O.A.P.), and liquid Pasteur B.C.G. administered by scarification. The durations of remission were compared with those of a similar group of thirty-three consecutive patients maintained on O.A.P. chemotherapy alone. Eleven of the twenty (55%) O.A.P.+ B.C.G. treated patients remain in remission with an estimated median duration of 91 weeks. Only 14 of 33 patients (42%) maintained on O.A.P. remain in remission with a median duration of 50 weeks (P= 0·03). Immunotherapy was significant only for patients with acute myeloblastic leukæmia (A.M.L.) and not for lymphoblastic or undifferentiated leukæmia. Thus, ten of fourteen A.M.L. patients maintained on O.A.P.+B.C.G. are in remission (median duration 72 + weeks) compared with nine of twenty-one O.A.P.-maintained patients (median duration 60 weeks) (P=0·04). General immunocompetence was augmented by B.C.G. The best prognostic immunological test was the patients' in-vitro lymphocyte blastogenic reactivity to autologous remission bone-marrow cells: all five patients who reacted vigorously have relapsed compared with none of the six who failed to react or reacted weakly.

UR - http://www.scopus.com/inward/record.url?scp=0016298455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016298455&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(74)90070-1

DO - 10.1016/S0140-6736(74)90070-1

M3 - Article

C2 - 4140327

AN - SCOPUS:0016298455

VL - 304

SP - 1405

EP - 1409

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 7894

ER -